



Published on *SWOT Analysis* (<https://www.swotanalysis.info>)

Home > Global Oral Peptide Drug Market Growth (Status and Outlook) 2022-2028

Global Oral Peptide Drug Market Growth (Status and Outlook) 2022-2028

Publication ID:

ARS1221045

Publication Date:

December 07, 2021

Pages:

112

Publisher:

Arsta

Region:

Global [1]

\$3,660.00

Publication License Type *

Single User License (PDF), \$3,660.00

Global License (PDF), \$5,860.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

As the global economy recovers in 2021 and the supply of the industrial chain improves, the Oral Peptide Drug market will undergo major changes. According to the latest research, the market size of

the Oral Peptide Drug industry in 2021 will increase by USD million compared to 2020, with a growth rate of %.

The global Oral Peptide Drug industry report provides top-notch qualitative and quantitative information including: Market size (2017-2021 value and 2022 forecast). The report also contains descriptions of key players, including key financial indicators and market competitive pressure analysis.

The report also assesses key opportunities in the market and outlines the factors that are and will drive the growth of the industry. Taking into account previous growth patterns, growth drivers, and current and future trends, we also forecast the overall growth of the global Oral Peptide Drug market during the next few years. The global Oral Peptide Drug market size will reach USD million in 2028, growing at a CAGR of % during the analysis period.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral Peptide Drug market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.

- Linaclotide
- Insulin
- Plecanatide
- Cyclosporine
- Octreotide

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.

- Hospital
- Retail Pharmacy

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

- Americas
 - United States
 - Canada
 - Mexico
 - Brazil
- APAC
 - China
 - Japan
 - Korea
 - Southeast Asia
 - India

Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.

Allergan
Novo Nordisk
Synergy Pharmaceuticals ?Salix?
Novartis
Chiasma

Table Of Contents:

Table of Content

1 Scope of the Report

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Oral Peptide Drug Market Size 2017-2028

2.1.2 Oral Peptide Drug Market Size CAGR by Region 2017 VS 2022 VS 2028

2.2 Oral Peptide Drug Segment by Type

2.2.1 Linaclotide

2.2.2 Insulin

- 2.2.3 Plecanatide
- 2.2.4 Cyclosporine
- 2.2.5 Octreotide
- 2.3 Oral Peptide Drug Market Size by Type
 - 2.3.1 Oral Peptide Drug Market Size CAGR by Type (2017 VS 2022 VS 2028)
 - 2.3.2 Global Oral Peptide Drug Market Size Market Share by Type (2017-2022)
- 2.4 Oral Peptide Drug Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Retail Pharmacy
- 2.5 Oral Peptide Drug Market Size by Application
 - 2.5.1 Oral Peptide Drug Market Size CAGR by Application (2017 VS 2022 VS 2028)
 - 2.5.2 Global Oral Peptide Drug Market Size Market Share by Application (2017-2022)
- 3 Oral Peptide Drug Market Size by Player
 - 3.1 Oral Peptide Drug Market Size Market Share by Players
 - 3.1.1 Global Oral Peptide Drug Revenue by Players (2020-2022)
 - 3.1.2 Global Oral Peptide Drug Revenue Market Share by Players (2020-2022)
 - 3.2 Global Oral Peptide Drug Key Players Head office and Products Offered
 - 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
 - 3.4 New Products and Potential Entrants
 - 3.5 Mergers & Acquisitions, Expansion
- 4 Oral Peptide Drug by Regions
 - 4.1 Oral Peptide Drug Market Size by Regions (2017-2022)
 - 4.2 Americas Oral Peptide Drug Market Size Growth (2017-2022)
 - 4.3 APAC Oral Peptide Drug Market Size Growth (2017-2022)
 - 4.4 Europe Oral Peptide Drug Market Size Growth (2017-2022)
 - 4.5 Middle East & Africa Oral Peptide Drug Market Size Growth (2017-2022)
- 5 Americas
 - 5.1 Americas Oral Peptide Drug Market Size by Country (2017-2022)
 - 5.2 Americas Oral Peptide Drug Market Size by Type (2017-2022)
 - 5.3 Americas Oral Peptide Drug Market Size by Application (2017-2022)
 - 5.4 United States
 - 5.5 Canada
 - 5.6 Mexico
 - 5.7 Brazil
- 6 APAC
 - 6.1 APAC Oral Peptide Drug Market Size by Region (2017-2022)

- 6.2 APAC Oral Peptide Drug Market Size by Type (2017-2022)
- 6.3 APAC Oral Peptide Drug Market Size by Application (2017-2022)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

- 7 Europe
- 7.1 Europe Oral Peptide Drug by Country (2017-2022)
- 7.2 Europe Oral Peptide Drug Market Size by Type (2017-2022)
- 7.3 Europe Oral Peptide Drug Market Size by Application (2017-2022)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

- 8 Middle East & Africa
- 8.1 Middle East & Africa Oral Peptide Drug by Region (2017-2022)
- 8.2 Middle East & Africa Oral Peptide Drug Market Size by Type (2017-2022)
- 8.3 Middle East & Africa Oral Peptide Drug Market Size by Application (2017-2022)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

- 10 Global Oral Peptide Drug Market Forecast
- 10.1 Global Oral Peptide Drug Forecast by Regions (2023-2028)
 - 10.1.1 Global Oral Peptide Drug Forecast by Regions (2023-2028)
 - 10.1.2 Americas Oral Peptide Drug Forecast
 - 10.1.3 APAC Oral Peptide Drug Forecast
 - 10.1.4 Europe Oral Peptide Drug Forecast
 - 10.1.5 Middle East & Africa Oral Peptide Drug Forecast
- 10.2 Americas Oral Peptide Drug Forecast by Country (2023-2028)

- 10.2.1 United States Oral Peptide Drug Market Forecast
- 10.2.2 Canada Oral Peptide Drug Market Forecast
- 10.2.3 Mexico Oral Peptide Drug Market Forecast
- 10.2.4 Brazil Oral Peptide Drug Market Forecast
- 10.3 APAC Oral Peptide Drug Forecast by Region (2023-2028)
 - 10.3.1 China Oral Peptide Drug Market Forecast
 - 10.3.2 Japan Oral Peptide Drug Market Forecast
 - 10.3.3 Korea Oral Peptide Drug Market Forecast
 - 10.3.4 Southeast Asia Oral Peptide Drug Market Forecast
 - 10.3.5 India Oral Peptide Drug Market Forecast
 - 10.3.6 Australia Oral Peptide Drug Market Forecast
- 10.4 Europe Oral Peptide Drug Forecast by Country (2023-2028)
 - 10.4.1 Germany Oral Peptide Drug Market Forecast
 - 10.4.2 France Oral Peptide Drug Market Forecast
 - 10.4.3 UK Oral Peptide Drug Market Forecast
 - 10.4.4 Italy Oral Peptide Drug Market Forecast
 - 10.4.5 Russia Oral Peptide Drug Market Forecast
- 10.5 Middle East & Africa Oral Peptide Drug Forecast by Region (2023-2028)
 - 10.5.1 Egypt Oral Peptide Drug Market Forecast
 - 10.5.2 South Africa Oral Peptide Drug Market Forecast
 - 10.5.3 Israel Oral Peptide Drug Market Forecast
 - 10.5.4 Turkey Oral Peptide Drug Market Forecast
 - 10.5.5 GCC Countries Oral Peptide Drug Market Forecast
- 10.6 Global Oral Peptide Drug Forecast by Type (2023-2028)
- 10.7 Global Oral Peptide Drug Forecast by Application (2023-2028)

- 11 Key Players Analysis
 - 11.1 Allergan
 - 11.1.1 Allergan Company Information
 - 11.1.2 Allergan Oral Peptide Drug Product Offered
 - 11.1.3 Allergan Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
 - 11.1.4 Allergan Main Business Overview
 - 11.1.5 Allergan Latest Developments
 - 11.2 Novo Nordisk
 - 11.2.1 Novo Nordisk Company Information
 - 11.2.2 Novo Nordisk Oral Peptide Drug Product Offered
 - 11.2.3 Novo Nordisk Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
 - 11.2.4 Novo Nordisk Main Business Overview
 - 11.2.5 Novo Nordisk Latest Developments
 - 11.3 Synergy Pharmaceuticals ?Salix?

11.3.1 Synergy Pharmaceuticals ?Salix? Company Information
11.3.2 Synergy Pharmaceuticals ?Salix? Oral Peptide Drug Product Offered
11.3.3 Synergy Pharmaceuticals ?Salix? Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Synergy Pharmaceuticals ?Salix? Main Business Overview
11.3.5 Synergy Pharmaceuticals ?Salix? Latest Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Oral Peptide Drug Product Offered
11.4.3 Novartis Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Novartis Main Business Overview
11.4.5 Novartis Latest Developments
11.5 Chiasma
11.5.1 Chiasma Company Information
11.5.2 Chiasma Oral Peptide Drug Product Offered
11.5.3 Chiasma Oral Peptide Drug Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Chiasma Main Business Overview
11.5.5 Chiasma Latest Developments
12 Research Findings and Conclusion

Companies Mentioned:

Allergan

Novo Nordisk

Synergy Pharmaceuticals ?Salix?

Novartis

Chiasma

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

Privacy Policy
TERMS & CONDITIONS
CONTACT

RECENT POSTS

What is SWOT Analysis?

March 12

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

Source URL:<https://www.swotanalysis.info/arsta/global-oral-peptide-drug-market-growth-status-and-outlook-2022-2028>

Links

[1] <https://www.swotanalysis.info/region/global>